


PerkinElmer adds new assay kits to aid GPCR therapeutic discovery

28 January 2021 | News

The new PerkinElmer offerings extend the company's leading GPCR analysis portfolio



PerkinElmer, a global leader committed to innovating for a healthier world, has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery.

The new PerkinElmer offerings extend the company's leading GPCR analysis portfolio, which includes innovative assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily and accurately characterise receptors, screen compounds and streamline workflows.

The new assays, which enable researchers to use the preferred cell models of their choice, include the HTRF GTP Gi binding kit, the industry's first TR-FRET based assay for GTP binding; the B-arrestin2 recruitment kit; and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2. These assays will help scientists continue to better understand the important role GPCRs play in disease by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signalling mechanisms.

Further, when the new kits are leveraged as part of PerkinElmer's comprehensive range of GPCR solutions, users can fully characterise the GPCRs being studied -- from ligand binding with the Tag-Lite® platform, and 2nd messenger with the cAMP and IP-One™ kits, to downstream GPCR signalling with hundreds of available assays.

Alan Fletcher, VP and GM of Life Sciences, PerkinElmer said, "By adding these new assays to our already robust GPCR

capabilities, we are giving researchers an end-to-end solution for continuing to unlock the role GPCRs play in disease so new and better therapeutics can be uncovered.”